Why Not Do Random Testing in Randomized Trials Designed to Measure Risk of Infection?

Key Takeaways

• Symptom-driven testing excludes mild/asymptomatic infections, inflating efficacy
• Random periodic testing would reveal lower relative vaccine efficacy
• Fragmented adverse‑event tables prevent calculating a true patient‑level harm rate
• Overlapping subsets and time windows hide frequent side effects
• Sponsors choose cheaper, narrative‑friendly designs over transparent, costly trials

Pulse Analysis

Randomized clinical trials for respiratory vaccines often adopt a symptom‑driven testing protocol, where only participants who report predefined symptoms within a tight window are swabbed. This design dramatically reduces the denominator of potential infections, allowing manufacturers to showcase higher relative vaccine efficacy (rVE) figures. By excluding asymptomatic or mildly symptomatic cases, the reported efficacy—such as the 34.5% figure highlighted in the Moderna flu trial—does not reflect real‑world performance, where many breakthrough infections go undetected. The practice aligns with regulatory allowances but creates a narrative that favors product approval and market uptake.

Safety reporting in these trials is equally compartmentalized. Adverse events are split across solicited and unsolicited categories, each collected from different participant subsets and time frames. The solicited adverse‑reaction data may cover only a few thousand subjects, while unsolicited events span the entire safety cohort of tens of thousands. Overlapping time windows and separate tables prevent analysts from aggregating a patient‑level incidence rate, effectively masking how many individuals experience any post‑vaccination symptom. This fragmentation inflates the perception of tolerability and shields sponsors from scrutiny over high‑frequency side effects.

The broader implication is a systematic erosion of trust in vaccine data. Regulators and health‑care providers rely on transparent, population‑level metrics to guide policy and clinical decisions. When trials avoid random testing and present safety data in opaque layers, the true risk‑benefit profile remains hidden, potentially leading to the adoption of less effective or riskier products. Policymakers could mandate random, periodic testing and unified safety databases to ensure that efficacy and harm are measured on the same denominator, restoring credibility and protecting public health.